The phase II RELATIVITY-106 trial (NCT05337137) [79] assessed the safety and efficacy of nivolumab plus bevacizumab with or without relatlimab, an anti-lymphocyte activation gene 3 (LAG3) antibody, in treatment-naïve patients with advanced/metastatic HCC [Table 5]. The gene discussed is LAG3; the disease is hepatocellular carcinoma.